Results 151 to 160 of about 1,685,955 (199)
International Journal of Cancer, Volume 159, Issue 8, Page 1873-1883, 15 October 2026.ABSTRACT Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers due to its asymptomatic progression, late‐stage diagnosis, and treatment resistance. Efforts in early detection have centered on identifying imaging features and liquid biopsy biomarkers capable of detecting PDAC and its high‐grade precursors before clinical symptoms ...
Christine Worthington +105 more
wiley +1 more source
Journal of Applied Clinical Medical Physics, Volume 27, Issue 10, October 2026.Abstract Background Breast Imaging Reporting and Data System (BI‐RADS) 4a nodules represent a diagnostic dilemma, with a malignancy rate ranging from 2% to 10%. The majority of these nodules prove benign after biopsy, leading to unnecessary invasive procedures, patient anxiety, and healthcare costs.
Jun Yang +5 more
wiley +1 more source
Oocyte–cumulus cell interaction: a key factor in early embryo development
Biological Reviews, Volume 101, Issue 5, Page 2265-2278, October 2026.ABSTRACT The evaluation of oocyte competence is a fundamental step in achieving successful outcomes following assisted reproduction techniques (ART). At present, however, conventional oocyte maturation assessment is carried out by morphological observation, which is a subjective method that does not consider molecular features.
Marc Torres‐Garrido +2 more
wiley +1 more source
Clinical Case Reports, Volume 14, Issue 10, October 2026.ABSTRACT Locoregional pathological complete response with concurrent radiologic metabolic remission following palliative gemcitabine–carboplatin chemotherapy in young, low‐grade metastatic triple‐negative breast cancer patient suggests potential chemosensitivity in select advanced cases, warranting further clinical investigation.
Shristi Gupta +5 more
wiley +1 more source
Az örökletes emlő- és petefészek tumor szindrómák 50%-ában mutatható ki a BRCA1 vagy a BRCA2 gének csírasejtes mutációja. 2019-2022 között a Debreceni Egyetem Klinika Központ (DE KK) Laboratóriumi Medicinában 951 egyén esetén történt meg a BRCA1/2 gének
Majoros, Viktória
core
Clinical Case Reports, Volume 14, Issue 10, October 2026.ABSTRACT In a patient with advanced ovarian cancer showing limited response to paclitaxel–carboplatin, adding sintilimab was associated with R0 cytoreduction and sustained disease‐free status during olaparib–bevacizumab maintenance. This case provides a rationale for further investigation of PD‐1 blockade as neoadjuvant therapy in carefully selected ...
Wang Zhenyan, Wang Yan
wiley +1 more source
International Journal of Cancer, Volume 159, Issue 7, Page 1735-1749, 1 October 2026.The detection of tumor‐infiltrating lymphocytes (TILs) is a positive prognostic factor in ovarian cancer. Moreover, TILs are significantly boosted by immunotherapy, though ovarian cancer patients have seen limited benefit from immune therapies. This study investigated the safety and feasibility of TIL therapy combined with PD‐1 and LAG‐3 inhibitors in ...
Tine J. Monberg +9 more
wiley +1 more source
Prevalence of Helicobacter pylori Exposure and Risk Factors Among BRCA1 and BRCA2 Carriers
International Journal of Cancer, Volume 159, Issue 7, Page 1663-1668, 1 October 2026.BRCA1 and BRCA2 pathogenic germline variant (PGV) carriers may be at increased risk of gastric cancer (GC), especially in the case of prior or active Helicobacter pylori (Hp) infection. The extent to which Hp influences BRCA1 and BRCA2‐associated GC remains uncertain. Here, the authors evaluated plasma samples from a U.S. cohort of BRCA1, BRCA2, PALB2,
Kole H. Buckley +12 more
wiley +1 more source
Learning Health Systems, Volume 10, Issue 4, October 2026.ABSTRACT Introduction The UK National Institute for Health and Care Excellence (NICE) produce guidelines that provide evidence‐based recommendations to support clinical care across England and Wales, but remain available in unstructured natural language form.
Ashvin Gupta +3 more
wiley +1 more source
Clinical and Molecular Features of BAP1‐Mutated Meningiomas: Case Series
Molecular Carcinogenesis, Volume 65, Issue 10, Page 1343-1350, October 2026.ABSTRACT BRCA1‐associated protein 1 (BAP1)‐deficient meningiomas represent a clinically and molecularly distinct subgroup with variable histology and aggressive behavior that may not be fully captured by current grading criteria. The clinical spectrum of BAP1 alterations in meningiomas, including both somatic and germline contexts, remains incompletely
Ivan Pradilla +7 more
wiley +1 more source